Shanghai XinHengRui Medical Secures Nearly RMB 100 Million Series A Funding to Advance Heart Failure Mechanical Circulatory Support Platform

VCBeat learned第一时间 that recently, Shanghai XIN HENG RUI Medical Technology Co., Ltd. ("XIN HENG RUI") has completed nearly 100 million yuan in A round financing, led by IDG Capital, with co-investment from Hygeia Capital and Beijing Lang Ma Feng VC LTD.. This round of financing will be mainly used for the registration clinical trials of the first product, OmniHeart Percutaneous Ventricular Assist Device, and to accelerate the research and development, clinical trials, and commercialization layout of existing and new products.

XIN HENG RUI was established in May 2021 in Minhang District, Shanghai, focusing on the research and development and industrialization of innovative medical devices for heart failure, and is committed to providing comprehensive, safe, and effective intelligent mechanical auxiliary treatment solutions for heart failure patients.

In clinical practice, heart failure patients have different disease progressions, and the demand for mechanical circulatory support devices varies at each stage. XIN HENG RUI Medical takes a multi-pronged approach, innovatively developing percutaneous ventricular assist devices, implantable ventricular assist devices, and implantable dual-heart assist devices to create a trinity of mechanical circulatory support devices more suitable for Chinese patients.

The first product, Omniheart Percutaneous Ventricular Assist Device, rapidly advanced from development to the clinical stage within just two years.Show "XIN HENG RUI Speed",In ChinaTake the leadSuccessfully applied in scientific research clinical trials, this type of product is expected to take the lead in conducting large-scale confirmatory clinical trials.

The founder of the company, Dr. Huang Lin,Graduated from Harbin Institute of Technology and Beihang University, with 10 years of experience in medical device R&D. Has worked for leading domestic and international medical device companies such as Medtronic, leading and participating in the development of multiple Class III medical devices.

Co-founder Mr. Jiang Haiyang,Graduated from Tsinghua University with a bachelor's and master's degree, possessing 15 years of experience in the aerospace and medical device industries. Formerly served as a senior project manager at MicroPort Cardiotech, responsible for the development project of transcatheter aortic valve.

The core team members all have more than 10 years of experience in the medical or related industries, and the R&D team spans professional fields such as fluid, mechanical, electronic, software, and materials.

Relying on its core technology platform, XIN HENG RUI has implemented a multi-pipeline product layout in the field of mechanical circulatory support for heart failure. For different stages of heart failure, XIN HENG RUI can provide the most personalized ventricular assist devices for effective treatment.

For high-risk PCI, cardiogenic shock, acute myocardial infarction, cardio-renal syndrome, and right-sided heart failure—common indications in the clinical stage of heart failure—the company's series of percutaneous ventricular assist devices can provide effective medium- to short-term circulatory support. For refractory end-stage heart failure, long-term implantable ventricular assist devices can be applied as a bridge to heart transplantation or for long-term treatment.

It is reported that in the future, XIN HENG RUI will also launch a dual-heart assist device and a total artificial heart to treat patients with biventricular heart failure.

The OmniHeart Percutaneous Ventricular Assist Device, independently developed by XIN HENG RUI Medical, boasts full independent intellectual property rights and exhibits significant advantages in multiple aspects:

• Efficient fluid design, high flow rate (above 4.0L/min), especially in terms of blood compatibility, with the hemolysis index NIH reduced by 90% compared to industry standards.Less damage to blood, with significantly superior product performance.

• Miniature Implantable Motor with Fully Independent Intellectual Property Rights, with advantages such as small size, high power density, good biocompatibility, and high reliability, it can operate continuously and stably for more than 7 days, meeting the treatment needs of high-risk PCI and most cardiogenic shock patients.

• Intelligent Safety Monitoring System, to judge the position and operating status of the blood pump through built-in algorithms, improve the safety of continuous operation in non-operating room environments (such as ICU, transport), and better meet clinical needs.
  

According to Dr. Huang Lin, founder of XIN HENG RUI, the research and development difficulties of percutaneous interventional ventricular assist devices lie not only in the overall flow field design, such as the fluid driving components (i.e., impeller configuration), hemodynamic design, etc., but also in solving issues related to the reliability, durability, biocompatibility, and temperature control of the implantable micro motor itself. This product has currently completed multiple core patent applications and is applying for the NMPA Innovative Medical Device Special Review Procedure.

Heart failure, known as the "final battlefield of heart disease," has an extremely high incidence and mortality rate, with a poor prognosis. Statistics show that the prevalence of heart failure in the 70-80 age group is as high as 20%, and 50% of patients die within five years of diagnosis. With the extension of survival periods for patients with heart disease, diabetes, and other conditions, along with the deepening degree of aging, the global number of heart failure patients will continue to grow. XIN HENG RUI's self-developed OmniHeart percutaneous ventricular assist device is expected to bring new hope for heart failure treatment to patients worldwide.

For this round of financing, XIN HENG RUI Founder Dr. Huang LinExpressed: "We are very grateful for the trust and support from all investors in XIN HENG RUI Healthcare. The success of this round of financing will promote the high-quality and rapid development of all product pipelines of XIN HENG RUI Healthcare. Based in China, XIN HENG RUI Healthcare always takes the clinical needs of domestic patients as its mission. We have the responsibility, confidence, and ability to bring the latest global technologies and cutting-edge products to more patients. Establishing a mechanical assist platform that aims at the synergy of innovative technologies and clinical needs, we will continue to deeply cultivate in the field of heart failure treatment, better serving Chinese heart failure patients."

Mr. Liu Yikun, Partner of IDG Capital"Heart failure is the only cardiovascular disease with a growing trend globally. As an innovative medical device company providing comprehensive mechanical circulatory support solutions, XIN HENG RUI Medical has achieved remarkable results within two years of its establishment. Starting from an innovative technology platform, adhering to professionalism and rigor, focusing on clinical needs, and efficiently advancing the research and development as well as clinical applications of multiple product lines, this gives us great confidence in the future development of XIN HENG RUI Medical. IDG Capital is delighted to join hands with XIN HENG RUI Medical to bring safer, more effective, and accessible high-end medical products to heart failure patients in China and around the world, offering personalized Chinese solutions for heart failure."

Dr. Du Jiangbo, Managing Partner of Hygeia Capital"As the number of PCI procedures increases, CTO lesion surgeries require better circulatory support devices. The high mortality rate associated with cardiogenic shock has also become an urgent clinical issue that needs to be addressed. With the release of large-scale global clinical evidence-based medical data, we believe that interventional circulatory support devices will become an important tool in assisting clinical treatment for heart failure. XIN HENG RUI Medical is a key player in this field, with a strong execution-capable team, a collaborative work environment, and solid technical expertise. The company possesses comprehensive platform-based technology and independent core component development capabilities, offering a rich pipeline of future extensible products. Hygeia Capital is delighted to collaborate with the XIN HENG RUI team. We will facilitate relevant industry resource cooperation to support the company’s growth, accelerating the advancement of innovative medical devices that meet China's clinical needs to benefit patients sooner."”

Yu Tianduo, Partner of Beijing Lang Ma Feng VC LTD.Mr. stated: "As the startup with the fastest pVAD R&D progress, the XIN HENG RUI team covers multiple disciplines such as motor, materials, fluid mechanics, machinery, and electronic control, demonstrating strong continuous R&D capabilities. The company’s products possess core independent intellectual property rights with controllable costs, offering competitive advantages for future commercialization. We hope the products can be approved soon to benefit patients both domestically and overseas. We are delighted to participate in the company's Series A financing."

IDG Capital is a globally leading private equity investment firm. After nearly 30 years of development, the company has cumulatively managed assets exceeding 150 billion RMB. Over the years, IDG Capital has consistently paid close attention to developments in the healthcare sector. In the past five years alone, IDG Capital has invested in approximately 70 projects within the medical field, focusing on key segments such as biopharmaceuticals, medical devices and diagnostics, artificial intelligence, and opportunities driven by policy changes that foster innovative healthcare models. In the biopharmaceutical space, IDG Capital has not only invested in new drug research and development companies like Kelun-Biotech, EdiGene, and Shengsi Biotech, but also in upstream and downstream enterprises in the industrial chain, including Singular Genomics, ZhenGe Biotech, Southern Model Organisms, and Novotech. Regarding medical devices and diagnostics, IDG Capital has funded projects like Yuanxin Technology, Huihe Medical, and Goodsky Biotech. In the artificial intelligence domain, IDG Capital has placed bets on projects such as Changmu Valley and Accutar Biotech. By closely monitoring adjustments in national health insurance policies and healthcare reforms, IDG Capital has identified standout projects like Weimai Healthcare and Simpler Healthcare.

Hygeia Capital was founded by Mr. Wang Kai in 2017, with offices in Shanghai and Chengdu. It is a professional investment institution focused on the healthcare and biotechnology sectors. The team has extensive industry background and experience in entrepreneurship/equity investment and capital operation. It has invested in more than 30 high-quality enterprises such as Kangdelai Medical (1501.HK), Cofoe Medical (301087.SZ), Vibe Biotech, Zed Bio, Zhongyi Anke, Rewiseley, Shengsi Biotech, Huajian Future, Ruiyi Technology, Junsai Biotech, EnerMed, and Yafei Pharmaceuticals. With the spirit of "Far-reaching Vision, Close Collaboration, Understanding through Investigation," and based on the dual-driven investment strategy of "VC Investment" + "Industry Empowerment," Hygeia Capital creates maximum investment value for investors and portfolio companies.

Beijing Lang Ma Feng Venture Capital LTD. has been established for over 15 years, investing in more than 200 companies cumulatively, with a management scale exceeding tens of billions. Focusing on hard technology investments and adhering to the value investing philosophy, it is committed to enabling investors to share in the growth achievements of great global enterprises.